Trius Therapeutics , Nasdaq: TSRX
Developing an antibiotic for serious gram-positive Staph infections.
Industry: Health Care
First Day Return: 0.0%
TSRX
Developing an antibiotic for serious gram-positive Staph infections.
| IPO Data | |
|---|---|
| IPO Date | 08/02/2010 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | San Diego, CA, United States |
| Founded | 2004 |
| Employees at IPO | 36 |
| Website www.triusrx.com | |
IPO News for Trius Therapeutics
Trius Therapeutics (TSRX) Performance
